Exelixis (EXEL) EBITDA Margin (2010 - 2026)
Exelixis (EXEL) posted quarterly EBITDA Margin of 41.15% for Q2 2026, up 751.0% year-over-year from 4.84% in Q2 2025, and up 4.73% quarter-over-quarter from 39.29% in Q1 2026.
Powered by 
Analysis
Exelixis (EXEL) EBITDA Margin (2010 - 2026) Analysis & Trends
Exelixis' EBITDA Margin history runs 17 years deep, the most recent figure standing at 41.15% for Q2 2026.
- In Q2 2026, EBITDA Margin rose 751.0% year-over-year to 41.15%; the TTM figure through Apr 2026 stood at 39.43% (up 628.0% YoY), while the FY2026 annual figure was 37.59%, up 971.0% from the prior year.
- EBITDA Margin for Q2 2026 stood at 41.15%, up from 39.29% in the prior quarter.
- The five-year high for EBITDA Margin was 43.3% in Q2 2024, with the low at 11.34% in Q4 2022.
- The 5-year median for EBITDA Margin is 23.38% (2022), against an average of 22.62%.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin plunged 2379 bps in 2023, then surged 2895 bps in 2024.
- Exelixis' EBITDA Margin stood at 11.34% in 2022, then soared by 250 bps to 17.05% in 2023, then soared by 48 bps to 25.22% in 2024, then soared by 57 bps to 39.57% in 2025, then climbed by 4 bps to 41.15% in 2026.
- Business Quant data shows EXEL's EBITDA Margin at 41.15% in Q2 2026, 39.29% in Q1 2026, and 39.57% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 39.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 39.51% |
| Apr 3, 2026 | 41.15% |
| Jan 2, 2026 | 39.29% |
| Oct 3, 2025 | 39.57% |
| Jul 4, 2025 | 37.58% |
| Apr 4, 2025 | 33.64% |
| Jan 3, 2025 | 28.80% |
| Sep 27, 2024 | 25.22% |
| Jun 28, 2024 | 43.30% |
| Mar 29, 2024 | 6.93% |
| Dec 29, 2023 | 17.05% |
| Sep 29, 2023 | -3.73% |
| Jun 30, 2023 | 16.57% |
| Mar 31, 2023 | 7.05% |
| Dec 30, 2022 | -11.34% |
| Sep 30, 2022 | 20.06% |
| Jul 1, 2022 | 19.96% |
| Apr 1, 2022 | 23.38% |
| Oct 1, 2021 | 15.72% |
| Jul 2, 2021 | 31.94% |